F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Exploring key safety data for cancer immunotherapy combinations
Date
14 Sep 2020Session
F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisionsPresenters
Philippe MerleAuthors
P. MerleAuthor affiliations
- Hôpital de la Croix-Rousse, 69317 - Lyon/FR
Resources
Resources from the same session
Welcome and introductions
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Tracking the recent advances within the field of unresectable HCC
Presenter: David Pinato
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Reviewing the latest phase III efficacy data for unresectable HCC
Presenter: Andrew Zhu
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Moving into the clinic: how will these data inform our clinical decisions?
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Panel discussion
Presenter: Philippe Merle
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast
Live Q&A - 24 September 2020 - 17:30-18:00
Presenter: Arndt Vogel
Session: F. Hoffmann-La Roche - Integrating cancer immunotherapy combinations into HCC practice: Duos, data and decisions
Resources:
Webcast